Monopar Therapeutics — Director's Dealing 2018

Jan 8, 2018

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Monopar Therapeutics (NONE)
CIK: 0001645469
Period of Report: 2018-01-08

Reporting Person: Tsuchimoto Kim R (N/A)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock options	$0.001		Common stock (21000)		Direct
Stock options	$0.001		Common stock (23520)		Direct

Footnotes

F1: Reflects the issuance of options to purchase up to 21,000 shares of common stock granted to Ms. Tsuchimoto on April 4, 2016 for her services as an officer of Monopar Therapeutics. The options vested 50% upon grant date, 25% upon the 6-month anniversary of grant date, and 25% upon the 1-year anniversary of grant date. The options each expire on April 3, 2026.

F2: Reflects the issuance of options to purchase up to 23,520 shares of common stock granted to Ms. Tsuchimoto on February 20, 2017 for her services as an officer of Monopar Therapeutics. The options vest 6/48ths on the six-month anniversary of the grant date and 1/48th on each subsequent one-month anniversary thereafter. The options each expire on February 19, 2027.